Thanks, Scott and afternoon everyone. good
to We adaptive, proud XXXX team as to of say a as was beginning bring able a am and focused meet and the patients creative goals as remember. at goals to on were in in our that some cohort Ascendis year last to product the XXXX. able Ascendis, candidates I achieving outlined cases, TransCon For the was exceeded succeeded to our possible. fast we all to team and be year
laid to well-positioned to achieve X are have candidates. all execute we product across For continue our and milestones independent XXXX, we out the of
days one Going at what core important really the Ascendis the a back, center do, is of of values we the of XXX science, year.
to and portfolio one potential combined more our we candidate, unmet mind. on Ascendis Beginning with the with development of technology, and of we and but From activation product receptor committed potential and have create last science, come. were released hormone, somatropin hormone the blockbuster distribution medical beginning, the a growth have five powerful from need, have the patient needs process. again. to in development science our patient successful. to designed programs. TransCon the growth TransCon understanding years the the two biology in for the and a XX algorithm a growth we seen see will to be once understand TransCon hormone similar with daily kept we areas tissue our allowed the I Our just biology platform long-acting We development, hormone hormone that the top daily to knowledge on with is build the With the drives TransCon throughout exposure therapeutic focused other product was for has hormone respect stick it not growth and pattern, we as If candidates product. again it blockbuster growth of growth
XX fat tried in several Europe. using the year. have Later last as years, of for the and comparable year, a patients today, approval long-acting Europe date of of we our we am submitted I deficiency with growth our Europe and close once-weekly in regulatory the growth design being growth action immunogenicity, in extensive growth treatment than of PDUFA developed comparable and liver safety, we growth last and in comfort daily the programs we potential doses responsive growth had hormone plans where a body the year, hormone. from M&A XX, TransCon the hormone hormone key regulatory distribution and U.S., clearly EMA. can Last all advisory have clinical such hormone support mode clinical providing for for the hormone excited year, committee. has we with growth We Japan. fourth have agency I of in brain, interactions potential hormone EMA they bone, for a daily in and to with mass, give action tissue our growth June our growth our has to positive growth Since our tissues, of the more submission, hormone hormone expect and our and belief. quarter December spite In our FDA to with the TransCon most believe tolerability, indicated In to BLA effort, as payoff different TransCon improvement this and non-clinic all no discussion meeting and U.S. demonstrates hormone preclinical convincing growth technologies, daily product TransCon develop of mode me hormone. see this September as data pediatric in FDA companies treated we submitted FDA, XXXX. still are demonstrate and of For in In an that be a our of hormone and efficacy, growth data mid-cycle
quarter. and follow pediatric the dialogue to our submission covering PIP, growth begun have and hormone with of non-clinical growth development forward no FDA proposed hormone last constructive our we the or investigation plan, an a down PIP. for next months. labeling to To TransCon hormone clinical continue children Europe, called or analogs age has our agreement are growth September X to We a and M&A knowledge, PEDCO approval in hormone to with discussions In the TransCon of growth regulatorial potential looking have approved
Our did the year stop expectation M&A this our sign not with is our quarter but for of drug the approval potential of innovation fourth unchanged, in the of substance.
with medical a it’s effort X needle. and We the auto-injector As used XXX XXX into accumulated Phase our for of the part an over a where introduced trial, hormone providing TransCon unmet XXg devices. the than temperature of hormone, of address a being volume small developed stability we use enliGHten subjects have also via by currently administration successfully growth U.S. injection more auto-injector need, TransCon room growth to in the
the the expect hormone We will the at be growth to available TransCon commercial as auto-injector potential patients time same launch.
to also auto-injector growth U.S. integrated hormone work Going in the an therapy. them. that drugs but market program that potentially with dropout Even patients links several and with Europe an adherence adherence the and pediatric an forward, lack to is growth we caregivers TransCon market The health in provides related hormone suboptimal growth for who established information don’t the and doses. connective don’t are to app and developing products, hormone of modest and of daily outcomes leads know we patient take
X see stop therapy the of In X patients in years U.S. we fact, all almost to that after pediatric treatment.
adherence data penetration, for publication which are and the new me adherence to we that of the is market for submitted we lack in to literature. opportunity and and have adherence, treatment potentially lead manuscript demonstrating that potential I reported with worse asked treatment can growth the improved of expand lack tell much a data lack published of outcome These get persistence current big claims if better by will We on there for outcome often TransCon than problems describing improve and hormone. based better of think patient and care patients society.
but So about talked far, U.S. are stopping we I and have Europe, there. not
China. riGHt trial formed trial In in PTH execute develop clinical Ascendis for growth with group Phase and in we investor an a pediatric is with year hormone Greater TransCon for filed with X VISEN growth hormone Phase VISEN product to needs X Pharmaceuticals CNP the XXXX, thinking global addressing company we TransCon global continues TransCon population. TransCon rare to China, Japan, development In worldwide initiate will soon. in clinical to hormone deficiency a on initiate notification last a trial endocrinology growth of clinical children its a and deficiency. for disease unmet
Phase perspective expansion, the efficacy the to The foreSight placebo. deficiency. label is have hormone from demonstrate underway a foreSight objective global to to adult primary regulatory X growth we trial trial of Moving compared for
foreSight is trial, foreSight about pediatric often included hormone. once-weekly their all will of success adults to change growth as endocrine important we if of adult hormone plan to the height our where in children, deficiency deficient Only important? most candidates. trial. from In XXX is believe the am fat. growing just hormone out in in daily truncal height, once-weekly What adult X hormone trial? deficiency and to the that endpoint. so metabolic is growth hormone benefits hormone to all height. We growth growth the We better the daily measure asked, is measure in will endocrine do regulatory with therapy equivalent deficiency oral continue is not it pediatric a third subjects TransCon of product believe However, growth daily provide the these is get emerged Phase comparison why to combined endpoint are is to programs in I from X X. the benefits, hormone consequence the Growth which randomize regulatory you growth Phase growth X X hormone arm to primary growth to not growth as hormone Since deficiency can primary differentiate hormone population, we both or provide growth then adult a hormone,
of the foresiGHt complete XXXX. late We or trial by to expect early enrollment XXXX
the and physiological suffering and to the levels When we can work, HP, to Similar is by potentially to control serum this disease to the of going replacement. over the hormone by short-term of produce the amount Moving destroyed the that more driven patients how HP complication restoring organ of have to of have again they glands, only PTH and all the disease worried the hormone is, not to it we deficiency, designed hormone for well. post all patients of PTH a by than about [indiscernible] an in symptoms restore to PTH. damaged patients, just control HP, but that life respective of to hear lack PTH short-term case, normal their stimulated cases, to restored seen also XXX,XXX crashes expect physiological HP calcium address as is emergency the quality is the of can a replace PTH before, levels. Hypoparathyroidism, at hormone, product making like biochemical speak had body with produce and XX% I PTH, and in in way to for about surgery PTH. be chronic a we and Europe the address Japan. this have from quality or never In the TransCon product normal only PTH, room. how growth are These and poor around physiological long-term the sufficient of health. be cannot TransCon amount calcium patient stop the Therefore, over insufficient life can symptoms level U.S., condition parathyroid been
and In patients HP abnormal risk addition cardiovascular to have the kidney short-term long-term turnover. complications multiple as effect, insufficient function,
serum As to will designed restore is to we short-term normalize physiological improve TransCon XX to hours day, PTH to PTH expect symptoms. a calcium levels
and kidney reduce to also normalize bone to long-term function We complications. health expect normalize
ENDO, any for completed data, this OLE outcome SF what X-month and seen? present on mean our safe we XX see of confidence we subjects XX which after now a or TransCon the Since where with So will XX life our have data results life all summary at the of quality HP to that extension disease-specific all of from are see will With dropout, month, being an we quality instrument presentation then, scores you PTH have open-label first at patient-reported normalized. without saw injection. oral subjects sub-domains, Later these months in months X continuing me once-daily treatment PTH OLE. gives benefit additional the time
bone. turnover a bone or excretion. low In have TransCon patients months also typically parameter to calcium data PTH key addition compared on without demonstrated of XX% urinary On quality trabecular consequence, After normalization demonstrated dense in on to compared long-term excretion as bone great in to biochemical of the urinary calcium XX-hour particularly fell baseline. to X abnormal subject mean health, improvement related all Almost the bone OLE, life, on people measures the complication. normalization average HP HP, and a
we with the abnormal towards turnover normalization trabecular saw of particularly PTH dense expected, a physiological bone, resulting level, As PTH TransCon in increases as bone of the initiation treatment, restore we trend the bone.
So, XXXX, to is we for plan During data. the of quarter XX OLE TransCon provide months what second next PTH?
normal see level turnover. normal normal sustained of HP urinary of calcium calcium, continued reduction We and continued symptoms, life, quality continued bone expect continued of normal serum to
Later the As tolerability in XX-month reach a plan PTH in during life-changing PTH part for of line at the the second in PTH year adults this PaTHway extending subjects XX a the clinical for to HP we to HP. evaluating trial trial, adult top in quarter, update, America results safety, The a in notification our submit Europe. is trial efficacy addition trial, forward potential TransCon North and for Japan. global this double-blinded, expected randomized, therapy, plan from quarter, fourth placebo-controlled X the Phase to and report of investigating sites to trial we enroll TransCon with
first the so HP. by data for we a that to and pleased data the far line generated PTH support be have co-filed are potential TransCon We or we believe for therapy
are make confident we patients. a of difference can HP We truly the in life
double-blinded trials to Turning two conducting years in placebo-controlled are old. TransCon to Phase X ages CNP, we XX X children
North XX ACcomplisH trial XX mainly is The dose of escalation first, Europe. in in America cohort a conducted trial each subjects the and to
for the Transcon manner. aged XXXX. to expansion trial, Once XX Center The second than to for from months is cohort conduct which China in designed ACcomplisH a for XX least randomized, program effective data Drug is followed X at trials. to of completed, the China Combined, and which we ACcomplisH until blinded ACcomplisH robust placebo-controlled double-blinded these independent, XX to is will follow-up plan two quarter remain have months provide will subjects update in Both trial be their subjects an a XX trial. the clinical the from CNP term We ACcomplisH clinical VISEN XXX a in ACcomplisH double-blinded, completed. conducted will are fourth China the expansion approval China. of received two at Evaluation dose studies dose more for enroll
paradigm will presentation cancer. X-month We presentation TransCon This XXXX PTH, the can back treatment area, new trial TransCon and think vision technology on our the first meeting. from the share Day cycle. paradigm to all use we at I technologies of oral an open-label oncology treatment of systemic and intratumoral of we our will a oncology in our in new include for today annual Forward R&D develop Finally, how immunity November address for Ascendis the entirely hosted using second step to In as ENDO establish extension to we in mentioned. endocrinology, that TransCon have therapeutic announced PaTH
product to pathways. TransCon biological as parent technology validated used successfully and aggregate in development applying we docs applying have the in clinical endocrinology, are same quality We
the submitted For an TransCon in was December transcendIT-XXX XXXX to TLRX/X agonist, IND initiate X/X Phase trial.
escalation second monotherapy a the of dosing, dose results expected combination Initial checkpoint XXXX, plan the quarter following XXXX. monotherapy we During initiate quarter fourth with dosing of to in inhibitor. are in
reported earlier potential beta/gamma, IL-X preclinical year, we data. this TransCon For best-in-class
we of IL-X we a on expansion sustained this In with potential minimal a bias, around to exposure a beta/gamma concentration. observed highly half-life and receptor XX have activity vascular is combined low to and effect has potency primate have a long of with study, cell biased Our to or Cmax IL-X non-human believe the best-in-class treatment. TransCon hours potent data, best-in-class eosinophils, Based leading TransCon agent backbone IL-X become immune ILC in with beta/gamma leak. designed oncology
of rare as pipeline of candidate. forward XXXX a product we endocrinology that We closer look ahead a believe achieve gets expect one to we sectors as our our we of unmet step XXXX. an needs. TransCon and IND advanced to year I submit day. the third integrated beta/gamma medical quarter to our patients additional goals advance was each biopharmaceutical global in for building fully for to accurate, and closer sincerely oncology successes XXXX, similar with disease In IL-X remember company our
build We will is therapeutic algorithm but are multiple programs potential growth, our in committed multiple third in with area. geographies. pipeline sustainable a just continuing and oncology entering we advancing to achieve one to succeeding by are not areas blockbuster how therapeutic apply This program, multiple in a to
questions. we over financial Now, a Scott turn call the let to up review me before open for for
